BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z. Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatol Int 2018;12:126-32. [PMID: 29637511 DOI: 10.1007/s12072-018-9856-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61. [PMID: 31541423 DOI: 10.1007/s12072-019-09988-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
2 Melikyan N, Huerga H, Atshemyan H, Kirakosyan O, Sargsyants N, Aydinyan T, Saribekyan N, Khachatryan N, Oganezova I, Falcao J, Balkan S, Hewison C. Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe. Open Forum Infect Dis 2021;8:ofaa653. [PMID: 33634203 DOI: 10.1093/ofid/ofaa653] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
4 Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Mahla RS. Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check. Aliment Pharmacol Ther 2018;48:233-4. [PMID: 29939413 DOI: 10.1111/apt.14795] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]
7 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
8 Elmekawy HA, Belal F, Abdelaziz AE, Abdelkawy KS, Ali AA, Elbarbry F. Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. Eur J Clin Pharmacol 2021;77:1369-79. [PMID: 33791829 DOI: 10.1007/s00228-021-03130-z] [Reference Citation Analysis]
9 Rao H, Yang X, Tan Y, Ning Q, Yang D, Wang J, Yang Y, Zheng S, Yang D, Hou J, Xie Q, Zhao C, Zhang L, Mao X, Sun T, Bai L, Zhang F, Jin J, Zhao Y, Wang M, Xie W, Ma Y, Quan J, Yan X, An P, Lin F, Jia J, Hu X, Gong Z, Wu J, Chen Y, Jia Z, Lin M, Wang G, Zhu Y, Zhang Y, Xie H, Luo L, Ren Q, Huang R, Wei L. Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. J Clin Transl Hepatol 2020;8:255-61. [PMID: 33083247 DOI: 10.14218/JCTH.2020.00031] [Reference Citation Analysis]
10 Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Nguyen KV, Lai CL, Chan HL, Wei L. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. J Viral Hepat. 2018;25:1429-1437. [PMID: 29974665 DOI: 10.1111/jvh.12965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Jiang X, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. Antiviral Res 2020;181:104871. [PMID: 32717286 DOI: 10.1016/j.antiviral.2020.104871] [Reference Citation Analysis]
12 Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;Epub ahead of print. [PMID: 32119034 DOI: 10.1001/jama.2019.20788] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
13 Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol 2020;11:710. [PMID: 32508646 DOI: 10.3389/fphar.2020.00710] [Cited by in F6Publishing: 2] [Reference Citation Analysis]